Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating activities
Net income	$ 31,951	$ 12,031
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	31,470	24,399
Amortization of deferred financing costs	2,944	2,516
Accretion of debt premium	(401)	(377)
Straight-line rental income, net	(3,420)	(2,998)
Rental income from intangible amortization, net	(539)	(1,097)
Non-cash stock-based compensation	3,602	10,930
Loss (gain) on sale of assets, net	2,458	(26)
Non-cash loss on extinguishment of debt	494	5,161
Loss on impairment	2,341
Reserve for uncollectible loan and other receivables	3,509	57
Changes in assets and liabilities:
Tenant receivables	(662)	(3,785)
Other assets	(545)	1,058
Accounts payable and accrued expenses	(6,395)	(9,468)
Tenant security deposits and other liabilities	3,281	(2,006)
Net cash provided by operating activities	70,088	36,395
Investing activities
Purchase of real estate	(368,870)	(38,076)
Proceeds from sales of real estate, net	1,337	4,842
Capital improvements	(10,293)	(9,909)
Development projects	(30,316)	(14,380)
Loan receivables received from others	7,613	3,222
Loan receivables funded to others	(12,410)	(2,707)
Net cash used in investing activities	(412,939)	(57,008)
Financing activities
Borrowings of debt	283,000	160,000
Repayment of debt	(128,117)	(353,203)
Payment of financing costs	(4,588)	(5,290)
Capital contributions	60	425
Proceeds from issuance of common stock	221,720	303,600
Cost of raising capital	(10,551)	(25,380)
Shares issued for settlement of vested stock and exercised stock options, net	3,053
Cash distributions to partners	(12,449)	(16,276)
Cash dividends to stockholders	(44,207)	(48,907)
Net cash provided by (used in) financing activities	307,921	14,969
Net decrease in cash and cash equivalents	(34,930)	(5,644)
Cash and cash equivalents:
Beginning of period	50,764	17,876
End of period	15,834	12,232
Supplemental cash flow information
Cash paid for interest	41,728	39,645
Supplemental disclosure of noncash activity
Accrued dividends payable to stockholders	17,009
Accrued distributions payable to partners	4,069
Write-off of straight-line rent receivable	1,380	2,887
Write-off of deferred financing costs, net	501	5,161
Aviv Healthcare Properties Limited Partnership
Operating activities
Net income	31,951	12,031
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	31,470	24,399
Amortization of deferred financing costs	2,944	2,516
Accretion of debt premium	(401)	(377)
Straight-line rental income, net	(3,420)	(2,998)
Rental income from intangible amortization, net	(539)	(1,097)
Non-cash stock-based compensation	3,602	10,930
Loss (gain) on sale of assets, net	2,458	(26)
Non-cash loss on extinguishment of debt	494	5,161
Loss on impairment	2,341
Reserve for uncollectible loan and other receivables	3,509	57
Changes in assets and liabilities:
Tenant receivables	(662)	(3,785)
Other assets	(545)	1,058
Accounts payable and accrued expenses	(6,395)	(9,468)
Tenant security deposits and other liabilities	3,281	(2,006)
Net cash provided by operating activities	70,088	36,395
Investing activities
Purchase of real estate	(368,870)	(38,076)
Proceeds from sales of real estate, net	1,337	4,842
Capital improvements	(10,293)	(9,909)
Development projects	(30,316)	(14,380)
Loan receivables received from others	7,613	3,222
Loan receivables funded to others	(12,410)	(2,707)
Net cash used in investing activities	(412,939)	(57,008)
Financing activities
Borrowings of debt	283,000	160,000
Repayment of debt	(128,117)	(353,203)
Payment of financing costs	(4,588)	(5,290)
Capital contributions	60	425
Proceeds from issuance of common stock	221,720	303,600
Cost of raising capital	(10,551)	(25,380)
Shares issued for settlement of vested stock and exercised stock options, net	3,053
Cash distributions to partners	(56,656)	(65,183)
Net cash provided by (used in) financing activities	307,921	14,969
Net decrease in cash and cash equivalents	(34,930)	(5,644)
Cash and cash equivalents:
Beginning of period	50,764	17,876
End of period	15,834	12,232
Supplemental cash flow information
Cash paid for interest	41,728	39,645
Supplemental disclosure of noncash activity
Accrued distributions payable to partners	21,078
Write-off of straight-line rent receivable	1,380	2,887
Write-off of deferred financing costs, net	$ 501	$ 5,161